3Ishibashi Y, MatsuiT, Takeuehi M, et al. Beneficial effects of metformin and irbesartan on advanced gly- cation end products (AGEs) - RAGE- in- duced proximal tubular cell injury [J]. Pharmacol Res, 2012,65:297 - 302.
4Matsuo H, Shigematsu H. Patient- based outcomes using the walking impairment questionn - aire for patients with peripheral arterial occlusive disease treated with Lpo - PGEI[J]. Cire J, 2010,74 : 365 - 370.
5Bai W, Zheng X, Zhou L, Li H. Prostaglandin E1 dose - de- pendently promotes stability of atherosclerotic plaque in arabbit model [J]. Can J Physiol Pharma- col,2012,90(2) : 131 - 139.
6Miller WL, Hartman KA. Response of novel biomar- kers to BNP infusin in patients withdecompensated heart failure; amultimarker paradigm[J]. J Cardivasc Transl Res,2009,2(4) :526- 535.
7Ronco C, Mccullough P, Anker SD, et al. Cardiorenal syndromes,report from the consen - sus conference of the acute dialysis quality initiative[J]. Eur Heart J,2010,31(6):703 - 711.
8Brandt LJ, Feuerstadt P, Blaszka MC. Anatomic pat- terns patient characteristics, and clinical outcomes in Isehemic colitis: a study of 313 cases supported by histology[J]. Am J Gastroentero, 2010, 105 (10).. 2245 - 2252.
9Raparia K, Usman I, Kanwar YS. Renal morphologic lesions reminiscent of diabelic neph- ropathy[J]. Arch Pathol Med,2013,137(3) :351 - 359.
